Exploring Neuropathology in the Post-COVID-19 Era

Dear Colleagues,

The COVID-19 pandemic strongly affected post-millennium society, changing the way that science and therapies must be developed for newly emerging global human infections, considering unprecedently faster multiprofessional efforts, and looking quickly to unknown long-term systemic sequalae. Some clinical symptoms have been extensively explored, such as lung and general inflammation, as have cardiovascular and kidney diseases, tiredness, myopathy, etc. These include memory and concentration problems, as part of neuropathological impairments, which are an open field for research. Neurological issues, especially chronic degenerative processes, have not yet been clarified, and the development of neuroprotection agents is also required. Risk factors associated with neuropathology have to be established, as was demonstrated for other viruses that affect the central nervous system, such as herpes simplex virus, human immunodeficiency virus, etc. In fact, we could also ask the following question: are COVID-19 neuropathologies a primary or secondary consequence of SARS-CoV-2 infection? Additionally, the role of neurodegeneration biomarkers in the context of COVID-19 is crucial, as many of these biomarkers have been found to be elevated in the cerebrospinal fluid of patients suffering from long COVID. Furthermore, inflammatory pathways are known to be dysregulated in neurodegeneration, highlighting the importance of understanding the relationship between inflammation and COVID-19. Lastly, the host genome plays a significant role in neuroinflammation, which may influence the neurological outcomes observed in COVID-19 patients. Therefore, this Special Issue seeks to gather groundbreaking discoveries and state-of-the-art reviews about the neuropathological consequences associated with COVID-19.

Dr. Rodrigo Portes Ureshino
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. COVID is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.